CA2291653A1 - Proteine facteur d'elongation 2 en tant que cible pour des antifongiques et des antiparasitaires - Google Patents

Proteine facteur d'elongation 2 en tant que cible pour des antifongiques et des antiparasitaires Download PDF

Info

Publication number
CA2291653A1
CA2291653A1 CA002291653A CA2291653A CA2291653A1 CA 2291653 A1 CA2291653 A1 CA 2291653A1 CA 002291653 A CA002291653 A CA 002291653A CA 2291653 A CA2291653 A CA 2291653A CA 2291653 A1 CA2291653 A1 CA 2291653A1
Authority
CA
Canada
Prior art keywords
compound
fungal
function
parasitic
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002291653A
Other languages
English (en)
Inventor
Jennifer Nielsen-Kahn
Michael C. Justice
Dennis M. Schmatz
Ming-Jo Hsu
Theresa W. Ku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714331.7A external-priority patent/GB9714331D0/en
Application filed by Individual filed Critical Individual
Publication of CA2291653A1 publication Critical patent/CA2291653A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Abstract

L'inhibition de la protéine appelée facteur d'élongation 2 fournit une cible qui permet d'identifier des composés antifongiques ou antiparasitaires potentiels. Les inhibiteurs du facteur d'élongation 2 conviennent comme agents thérapeutiques contre les infections fongiques ou parasitaires.
CA002291653A 1997-06-10 1998-06-09 Proteine facteur d'elongation 2 en tant que cible pour des antifongiques et des antiparasitaires Abandoned CA2291653A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4927197P 1997-06-10 1997-06-10
US60/049,271 1997-06-10
GB9714331.7 1997-07-07
GBGB9714331.7A GB9714331D0 (en) 1997-07-07 1997-07-07 Protein elongation factor 2 as a target for antifungal and antiparasitic agents
PCT/US1998/011903 WO1998057176A1 (fr) 1997-06-10 1998-06-09 Proteine facteur d'elongation 2 en tant que cible pour des antifongiques et des antiparasitaires

Publications (1)

Publication Number Publication Date
CA2291653A1 true CA2291653A1 (fr) 1998-12-17

Family

ID=26311848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002291653A Abandoned CA2291653A1 (fr) 1997-06-10 1998-06-09 Proteine facteur d'elongation 2 en tant que cible pour des antifongiques et des antiparasitaires

Country Status (5)

Country Link
EP (1) EP0995120A1 (fr)
JP (1) JP2002511933A (fr)
AU (1) AU741017B2 (fr)
CA (1) CA2291653A1 (fr)
WO (1) WO1998057176A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7885665B2 (en) 2003-09-26 2011-02-08 Siemens Enterprise Communications, Inc. System and method for failsafe presence monitoring

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
EP0652888A1 (fr) * 1990-08-16 1995-05-17 Isis Pharmaceuticals, Inc. INHIBITION DE $i(CANDIDA)
JPH09504176A (ja) * 1993-10-25 1997-04-28 ライボジーン、インコーポレイテッド 抗真菌剤の選抜法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7885665B2 (en) 2003-09-26 2011-02-08 Siemens Enterprise Communications, Inc. System and method for failsafe presence monitoring

Also Published As

Publication number Publication date
JP2002511933A (ja) 2002-04-16
EP0995120A1 (fr) 2000-04-26
AU741017B2 (en) 2001-11-22
AU8062798A (en) 1998-12-30
WO1998057176A1 (fr) 1998-12-17

Similar Documents

Publication Publication Date Title
Van den Bossche et al. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis
Urbina et al. Inhibitors of the fungal cell wall. Synthesis of 4-aryl-4-N-arylamine-1-butenes and related compounds with inhibitory activities on β (1–3) glucan and chitin synthases
Hall et al. The quorum-sensing molecules farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans
JP4376297B2 (ja) マラリア原虫のｇｐｉの生合成を阻害する化合物をスクリーニングする方法
Creppy et al. Effects of ochratoxin A metabolites on yeast phenylalanyl-tRNA synthetase and on the growth and in vivo protein synthesis of hepatoma cells
Venkateswarlu et al. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug
US6303302B1 (en) Regulation of fungal gene expression
Liu et al. Role of a VPS41 homologue in starvation response, intracellular survival and virulence of Cryptococcus neoformans
US6096511A (en) Protein elongation factor 2 as a target for antifungal and antiparasitic agents
Monod et al. Secreted proteinases and other virulence mechanisms of Candida albicans
Strijbis et al. Carnitine-dependent transport of acetyl coenzyme A in Candida albicans is essential for growth on nonfermentable carbon sources and contributes to biofilm formation
Breakspear et al. Npc1 is involved in sterol trafficking in the filamentous fungus Fusarium graminearum
Kouvelis et al. Assessing the cytotoxic and mutagenic effects of secondary metabolites produced by several fungal biological control agents with the Ames assay and the VITOTOX® test
AU741017B2 (en) Protein elongation factor 2 as a target for antifungal and antiparasitic agents
Finkel et al. Application of the systematic “DAmP” approach to create a partially defective C. albicans mutant
US20020160441A1 (en) Protein elongation factor 2 as a target for antifungal and antiparasitic agents
Ulaszewski et al. A new mutation for multiple drug resistance and modified plasma membrane ATPase activity in Schizosaccharomyces pombe
Barrett-Bee et al. Biochemical changes associated with the antifungal action of the triazole ICI 153,066 on Candida albicans and Trichophyton quinckeanum
PT626454E (pt) Pesquisa de corpos polares de fuso para fungicidas
Zhang et al. The usnic acid derivative peziculone targets cell walls of Gram-positive bacteria revealed by high-throughput CRISPRi-seq analysis
JP4498930B2 (ja) 真菌感染およびガンの治療に使用するための、地衣植物（Ｅｖｅｒｎｉａｓｔｒｕｍｃｉｒｒｈａｔｕｍ）由来のメチル−β−オルシノールカルボキシラート
Kelly et al. Sterol 14 α-Demethylase: Target of the Azole Antifungal Agents
EP0644268A2 (fr) Dépistage de stérol-delta-14-réductase
EP1573049B1 (fr) Utilisation de la mss4 comme cible antifongique
Myers et al. Penicillin-binding proteins of Rhodospirillum rubrum

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead